Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC). Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Hanna, NH
  • Einhorn, L
  • Sandler, A
  • Langer, C
  • Hariharan, S
  • Ansari, R
  • Ellis, Peter
  • Byrne, M
  • Wang, B
  • Bunn, P

publication date

  • June 1, 2005